Drug Profile


Latest Information Update: 16 Nov 2000

Price : $50

At a glance

  • Originator Helopharm
  • Developer Boehringer Ingelheim; Helopharm
  • Class Class Ic antiarrhythmics; Propiophenones; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Ventricular arrhythmias

Most Recent Events

  • 16 Nov 2000 No-Development-Reported for Ventricular arrhythmias in Germany (PO)
  • 17 May 1995 A study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top